Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of ALT 2074 in Subjects With Type 2 Diabetes Who Have a Haptoglobin Type 2-2 Genotype and Coronary Artery Disease

NCT00491543 is registered in ClinicalTrials.gov with Synvista Therapeutics, Inc as lead sponsor.

NCT NCT00491543
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00491543 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of ALT 2074 in Subjects With Type 2 Diabetes Who Have a Haptoglobin Type 2-2 Genotype and Coronary Artery Disease
Lead sponsor
Synvista Therapeutics, Inc
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2007
Completion date
May 31, 2008
Enrollment
66 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

coronary artery disease, diabetes